Feasibility study of trastuzumab (T) and pertuzumab (P) added to neoadjuvant chemoradiotherapy (nCRT) in resectable HER2+esophageal adenocarcinoma (EAC) patients (pts): The TRAP study
Author(s):
Schokker, S.; Molenaar, R.J.; Meijer, S.L.; Mathot, R.A.A.; Woude, S. van der; Krishnadath, S.K.; Creemers, G.J.; Nieuwenhuijzen, G.A.P.; Sangen, M. van der; Beerepoot, L.V.; Heisterkamp, J.; ; Slingerland, M.; Cats, A.; Hospers, G.; Bijlsma, M.F.; Punt, C.J.A.; Henegouwen, M.I.V.; Hulshof, M.C.; Laarhoven, H.W.M. van
